A Phase II Study of Olaparib Plus Cediranib in Combination With Standard Therapy for Small Cell Lung Cancer

Trial Profile

A Phase II Study of Olaparib Plus Cediranib in Combination With Standard Therapy for Small Cell Lung Cancer

Suspended
Phase of Trial: Phase II

Latest Information Update: 16 Oct 2017

At a glance

  • Drugs Cediranib (Primary) ; Olaparib (Primary) ; Carboplatin; Cisplatin; Etoposide
  • Indications Neuroendocrine carcinoma; Small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 29 May 2017 Status changed from recruiting to suspended.
    • 11 Apr 2017 Planned primary completion date changed from 1 Dec 2018 to 1 Apr 2020.
    • 11 Apr 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top